Publications by authors named "Gabi Rink"
Introduction: The molecular diagnosis of the A blood group is based on the exclusion of gene variants causing blood groups A, B, or O. A specific genetic marker for the A blood group is still missing. Recently, long-read ABO sequencing revealed four sequence variations in intron 1 as promising markers for the * allele.
View Article and Find Full Text PDFArticle Synopsis
- The study investigated the levels of soluble P-selectin (sP-sel), a marker for platelet activation, in individuals who recovered from moderate COVID-19 and compared these levels to non-infected controls.
- The research included 154 convalescent donors and 111 controls, measuring sP-sel plasma concentrations at three time points after COVID-19 diagnosis.
- Results showed that convalescent donors had significantly higher sP-sel levels than controls at the first two time points, but levels decreased over time and became comparable by the third measurement.
Background: Noninvasive prenatal testing (NIPT) for fetal antigens is a common standard for targeted immune prophylaxis in RhD-mediated hemolytic disease of the fetus and newborn, and is most frequently done by quantitative PCR (qPCR). A similar approach is considered for other blood group and human platelet alloantigens (HPA). Because of a higher sensitivity compared to qPCR for rare molecule detection, we established and validated digital PCR (dPCR) assays for the detection of exons 3, 5 and 7, KEL1, HPA-1a, and HPA-5b from cell-free DNA (cfDNA) in plasma.
View Article and Find Full Text PDFBackground: The human platelet alloantigens (HPA) HPA-1a and HPA-5b are located on glycoproteins on the platelet surface and are the most relevant to cause neonatal alloimmune thrombocytopenia (NAIT). The antigens are defined by single nucleotide polymorphisms (SNPs) in the glycoprotein genes, and the antigen status can be determined by genotyping the SNPs. However, genotyping is time-consuming and costly depending on the method and sample throughput.
View Article and Find Full Text PDFBackground: The provision of compatible blood products to patients is the most essential task of transfusion medicine. Besides ABO and Rh, a number of additional blood group antigens often have to be considered for the blood supply of immunized or chronically transfused patients. It also applies for platelet antigens (HPA) and neutrophil antigens (HNA) for patients receiving platelet or granulocyte concentrates.
View Article and Find Full Text PDFBackground: The detection and identification of antibodies to red blood cell (RBC) antigens is one of the most important and challenging issues in transfusion medicine. Up to date there are 354 RBC antigens recognized by the International Society of Blood Transfusion (ISBT). The reagent RBCs used in commercial antibody screening and identification panels however are usually serologically typed for up to 40 clinically important antigens.
View Article and Find Full Text PDFMolecular Screening for Vel- Blood Donors in Southwestern Germany.
Transfus Med Hemother
November 2015
Background: The SMIM1 protein carries the Vel blood group antigen, and homozygosity for a 17 bp deletion in the coding region of the SMIM1 gene represents the molecular basis of the Vel- blood group phenotype. We developed PCR-based methods for typing the SMIM1 17 bp (64-80del) gene deletion and performed a molecular screening for the Vel- blood type in German blood donors.
Methods: For SMIM1 genotyping, TaqMan-PCR and PCR-SSP methods were developed and validated using reference samples.
Background: Contamination of cell culture and biological material by mollicute species is an important safety issue and requires testing. We have developed a singletube real-time polymerase chain reaction (PCR) assay for rapid detection of Mollicutes species stipulated by the European Pharmacopeia.
Methods: Primers and TaqMan probes (FAM-labeled) were deduced from 16S rDNA sequence alignment of 18 mollicutes species.